Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Keytruda Top-Selling Drug in Japan for 23 Months Running: Encise
September 5, 2025
- Eisai Begins FDA Rolling Submission for Leqembi SC for Starting Dose
September 4, 2025
- FDA Accepts Xocova NDA for COVID Post-Exposure Prophylaxis
September 4, 2025
- Bayer Pushes Cross-Border Open Innovation with New Co.Lab Connect Program
September 4, 2025
- ASKA Repeats Request to Dalton after Dismissive Email on Stake Plan
September 3, 2025
- Kaken’s Hyperhidrosis Drug Ecclock Gets Approval in South Korea
September 3, 2025
- Mitsubishi Tanabe Releases OD Tablet Form of Canalia in Japan
September 3, 2025
- Fuji, Nitto Strike Sales Deal for Eylea Biosimilar, Eye November Listing
September 2, 2025
- Shionogi Completes Full Takeover of Torii under JT Deal
September 2, 2025
- Teva Takeda Renamed as T’s Pharma
September 2, 2025
- FDA Clears Leqembi Autoinjector; Launch Set for Oct. 6
September 2, 2025
- Santen’s Glaucoma Drug Tapcom Launched in China
September 2, 2025
- Takeda Wins Japan Approval for Takhzyro Pen Formulation
September 2, 2025
- Specialist Highlights Lfynua’s Potential for Refractory Chronic Cough
September 1, 2025
- Medipal, JCR Expand Tie-Up to GM2 Gangliosidosis Drug JR-479
September 1, 2025
- NEC Touts AI as Core of Personalized Cancer Vaccine Development
September 1, 2025
- Meiji Bags Japan Approval for 2-Dose COVID Vaccine Vial
September 1, 2025
- Mitsubishi Tanabe Taps Ex-Pfizer Japan Chief as CEO, Ex-Takeda CFO as Chairman
August 29, 2025
- Resilire Seeks to Double Pharma Clients for Supply Chain Visualization Platform
August 29, 2025
- Novo Hooks Up with Hirosaki City on Obesity Program for Young Adults
August 29, 2025
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…